These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29751121)

  • 21. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Van Schalkwyk M; Bekker A; Decloedt E; Wang J; Theron GB; Cotton MF; Eke AC; Cressey TR; Shapiro DE; Bacon K; Knowles K; George K; Browning R; Chakhtoura N; Rungruengthanakit K; Wiesner L; Capparelli EV; Stek AM; Mirochnick M; Best BM;
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0073723. PubMed ID: 37882552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
    Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
    Wu L; Ye Z; Liu H; Guo H; Lin J; Zheng L; Chu N; Liu X
    J Pharm Biomed Anal; 2020 Feb; 180():113076. PubMed ID: 31896523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
    Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH
    Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
    Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of First-Line Anti-Tubercular Drugs.
    Mukherjee A; Lodha R; Kabra SK
    Indian J Pediatr; 2019 May; 86(5):468-478. PubMed ID: 30915644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
    Mtabho CM; Semvua HH; van den Boogaard J; Irongo CF; Boeree MJ; Colbers A; Burger DM; van Crevel R; van der Ven AJAM; Kibiki GS; Tostmann A; Aarnoutse RE
    J Antimicrob Chemother; 2019 Dec; 74(12):3537-3545. PubMed ID: 31651031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drug monitoring in the treatment of tuberculosis patients.
    Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
    Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.
    Parsons TL; Marzinke MA; Hoang T; Bliven-Sizemore E; Weiner M; Mac Kenzie WR; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6747-57. PubMed ID: 25182637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
    Babalık A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildiz L; Çarpaner E
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1442-7. PubMed ID: 24125448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
    Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
    Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
    Van Aartsen D; Justine M; Mduma E; Mpagama SG; Alshaer MH; Peloquin CA; Mujaga B; Maro A; Gratz J; Kosek M; Liu J; Rogawski McQuade ET; Houpt ER; Thomas TA; Heysell SK
    Lancet Microbe; 2022 Jun; 3(6):e408-e416. PubMed ID: 35659902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
    Mallikaarjun S; Wells C; Petersen C; Paccaly A; Shoaf SE; Patil S; Geiter L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5976-85. PubMed ID: 27458223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.